newsfilter
← Latest News
Business Wire·

Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it received approval from the New York State (NYS) Clinical Laboratory Evaluation Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA (ctDNA) assay. The CLEP regulates and seeks to ensure the accuracy and reliability of test results in clinical laboratories located in or accepting specimens from NYS. With the approval of FoundationACT, the company’s suite of comprehensive genomic profiling products is available to oncologists and patients in all 50 states.